Devanand Sarkar and a team of scientists at VCU Massey Comprehensive Cancer Center have discovered that the gene TAF2 plays a pivotal role in the growth of hepatocellular carcinoma. The researchers found that TAF2 is overexpressed in HCC patients compared to individuals with healthy livers, and that TAF2 regulates the survival of hepatocytes—the functional cells of the liver—and tumor formation. Their study—recently published in the journal Hepatology also demonstrates that TAF2 cooperates with the MYC gene, another known major driver of cancer, to accelerate tumor growth.
Little is known about what causes ovarian cancer, and there is no way to detect it early. Now, an accidental finding in a 22-year-old patient has given Mayo Clinic researchers a new lead.
FDA granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy.
FDA has granted Breakthrough Therapy Designation to daraxonrasib, a RAS(ON) multi-selective inhibitor, for previously treated metastatic PDAC in patients with KRAS G12 mutations.
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone, also called VRd, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. A final decision is expected in the coming months.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program.
In the fiscal year 2026 budget request, the Trump administration proposes “forward funding,” or multiyear funding, of awards.
A federal judge has called the Trump’s administration’s cancellation of NIH grants “illegal,” striking it down.
NIH Director Jay Bhattacharya has launched his own podcast called “The Director’s Desk,” where he plans to host weekly conversations on scientific careers, leadership, and innovation at NIH.
